311 related articles for article (PubMed ID: 17420764)
1. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
2. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
3. The immunotherapy of prostate and bladder cancer.
Totterman TH; Loskog A; Essand M
BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
[TBL] [Abstract][Full Text] [Related]
4. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccines for the treatment of prostate cancer.
Lehrfeld TJ; Lee DI
Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
[TBL] [Abstract][Full Text] [Related]
6. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer.
Muir G; Rajbabu K; Callen C; Fabre JW
BJU Int; 2006 Nov; 98(5):989-95. PubMed ID: 16879440
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer immunology: biology, therapeutics, and challenges.
Webster WS; Small EJ; Rini BI; Kwon ED
J Clin Oncol; 2005 Nov; 23(32):8262-9. PubMed ID: 16278482
[TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
12. Immunologic targeting: how to channel a minimal response for maximal outcome.
Slovin SF
Curr Opin Urol; 2006 May; 16(3):179-85. PubMed ID: 16679856
[TBL] [Abstract][Full Text] [Related]
13. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
14. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
15. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
16. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
Qi SY; Wang M; Xu Y
Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation.
Waeckerle-Men Y; Allmen EU; von Moos R; Classon BJ; Scandella E; Schmid HP; Ludewig B; Groettrup M; Gillessen S
Prostate; 2005 Sep; 64(4):323-31. PubMed ID: 15754347
[TBL] [Abstract][Full Text] [Related]
18. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
20. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
